Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13096 | 0.97 | IDO1 (0.58) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL467215 | 0.95 | IDO1 (0.56) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL6157954 | 0.91 | LTA4H (0.54) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL8993257 | 0.91 | LTA4H (0.65) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL2996706 | 0.91 | MAOB (0.59) | IDO1CA12CA1CA2CA7 | |
| (Chloromethyl)Benzene SCHEMBL28005139 | 0.89 | LTA4H (0.69) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL28148603 | 0.87 | IDO1 (0.48) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL5505882 | 0.85 | APP (0.67) | IDO1AGXTALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28784521 | 0.85 | APP (0.67) | IDO1AGXTALDH1A1MAPTSMN1; SMN2 | |
| Bicarbonate SCHEMBL28421098 | 0.83 | CA1 (0.52) | IDO1CA1CA2ALDH1A1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELLTAXIS, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | Celltaxsis, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200308181-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2020-10-01 | — | — | US | disclosed |
| EP-3205644-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1976828-B1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160272649-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-09-22 | — | — | US | disclosed |
| US-9315509-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | DOMAIN PARTNERS VIII, L.P. | 2015-03-19 | — | — | US | disclosed |
| US-20080161363-A1 | 2-Aminopyridine Compounds Useful as Beta-Secretase Inhibitors For the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1807396-A1 | 2-AMINOPYRIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007079078-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155726-A1 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
| WO-2006060109-A1 | 2-AMINOPYRIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| EP-1656368-A2 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | PYM1, GPR119, GLP1R | IDO1 3205/4885CA12 2479/4885CA1 2862/4885 |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20070155726-A1 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20200308181-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20160272649-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | IDO1 941/4885CA12 3751/4885CA1 1259/4885 |
| US-20080161363-A1 | 2-Aminopyridine Compounds Useful as Beta-Secretase Inhibitors For the Treatment of Alzheimer's Disease | BACE1, BACE2, APP | IDO1 1677/4885CA12 3791/4885CA1 910/4885 |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GPR119, SLC5A2, GLP1R | IDO1 2525/4885CA12 2448/4885CA1 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.